These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14722202)

  • 41. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D; Plasencia C; Ramiro S; Nuño L; Bonilla G; Nagore D; Ruiz Del Agua A; Martínez A; Aarden L; Martín-Mola E; Balsa A
    Rheumatology (Oxford); 2011 Aug; 50(8):1445-52. PubMed ID: 21427177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis.
    Temekonidis TI; Georgiadis AN; Alamanos Y; Bougias DV; Voulgari PV; Drosos AA
    Ann Rheum Dis; 2002 Sep; 61(9):822-5. PubMed ID: 12176808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The BeSt way of withdrawing biologic agents.
    Allaart CF; Lems WF; Huizinga TW
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
    Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R
    Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.
    Peters MJ; Vis M; van Halm VP; Wolbink GJ; Voskuyl AE; Lems WF; Dijkmans BA; Twisk JW; de Koning MH; van de Stadt RJ; Nurmohamed MT
    Ann Rheum Dis; 2007 Jul; 66(7):958-61. PubMed ID: 17314120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
    van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J;
    Lancet; 2012 May; 379(9827):1712-20. PubMed ID: 22464340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab.
    Hermann J; Mueller T; Fahrleitner A; Dimai HP
    Clin Exp Rheumatol; 2003; 21(4):473-6. PubMed ID: 12942699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study.
    van der Maas A; Kievit W; van den Bemt BJ; van den Hoogen FH; van Riel PL; den Broeder AA
    Ann Rheum Dis; 2012 Nov; 71(11):1849-54. PubMed ID: 22504561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
    van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
    Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
    Klarenbeek NB; Güler-Yüksel M; van der Kooij SM; Han KH; Ronday HK; Kerstens PJ; Seys PE; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Jun; 70(6):1039-46. PubMed ID: 21415052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.
    Ariza-Ariza R; Navarro-Sarabia F; Hernández-Cruz B; Rodríguez-Arboleya L; Navarro-Compán V; Toyos J
    Rheumatology (Oxford); 2007 Mar; 46(3):529-32. PubMed ID: 17012439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
    Abe T; Takeuchi T; Miyasaka N; Hashimoto H; Kondo H; Ichikawa Y; Nagaya I
    J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
    Pavelka K; Jarosová K; Suchý D; Senolt L; Chroust K; Dusek L; Vencovský J
    Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.